Liraglutide is marketed in Europe as Victoza® (1.2 mg/1.8 mg), indicated for glycaemic control in type 2 diabetes, and Saxenda® (3.0 mg), indicated for weight management in adults with obesity. We performed a post-authorization safety study (PASS) to assess the in-market use of Saxenda® and Victoza® according to approved indications and posology.

Sbraccia, P., Aberle, J., Olsen, A.h., Rathor, N., Major-Pedersen, A. (2023). Investigating the potential non-authorized use of two different formulations of liraglutide in Europe: A real-world drug utilization study. DIABETES, OBESITY AND METABOLISM, 25(4), 985-991 [10.1111/dom.14945].

Investigating the potential non-authorized use of two different formulations of liraglutide in Europe: A real-world drug utilization study

Sbraccia, Paolo;
2023-12-13

Abstract

Liraglutide is marketed in Europe as Victoza® (1.2 mg/1.8 mg), indicated for glycaemic control in type 2 diabetes, and Saxenda® (3.0 mg), indicated for weight management in adults with obesity. We performed a post-authorization safety study (PASS) to assess the in-market use of Saxenda® and Victoza® according to approved indications and posology.
13-dic-2023
Pubblicato
Rilevanza internazionale
Articolo
Esperti anonimi
Settore MED/09 - MEDICINA INTERNA
Settore MEDS-05/A - Medicina interna
English
Antiobesity drug
GLP-1 analogue
incretin therapy
liraglutide
obesity therapy
Sbraccia, P., Aberle, J., Olsen, A.h., Rathor, N., Major-Pedersen, A. (2023). Investigating the potential non-authorized use of two different formulations of liraglutide in Europe: A real-world drug utilization study. DIABETES, OBESITY AND METABOLISM, 25(4), 985-991 [10.1111/dom.14945].
Sbraccia, P; Aberle, J; Olsen, Ah; Rathor, N; Major-Pedersen, A
Articolo su rivista
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2108/310536
Citazioni
  • ???jsp.display-item.citation.pmc??? 0
  • Scopus 0
  • ???jsp.display-item.citation.isi??? 0
social impact